Abstract
Objectives: To associate the early change in DL-CT parameters and HU with survival outcomes and treatment response in patients with metastatic renal cell carcinoma (mRCC). Methods: DL-CT scans were performed at baseline and after 1 month of checkpoint immunotherapy or tyrosine kinase inhibitor therapy. Scans were reconstructed to conventional CT and DL-CT series, and used for assessment of HU, iodine concentration (IC), and the effective atomic number (Zeffective) in the combined RECISTv.1.1 target lesions. The relative changes, defined as ΔIC(combined), ΔZeffective(combined), and ΔHU(combined), were associated with progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). The reduction in the sum of diameters of target lesions ≥ 30% after 1 month was associated with OS, PFS, and ORR. Results: Overall, 115 and 104 mRCC patients were included at baseline and 1 month, respectively. Median IC(combined) decreased from 2.3 to 1.2 mg/ml (p < 0.001), Zeffective(combined) from 8.5 to 8.0 (p < 0.001), and HU(combined) from 86.0 to 64.00 HU (p < 0.001). After multivariate adjustments, the largest reductions in ΔIC(combined) (HR 0.47, 95% CI: 0.24–0.94, p = 0.033) and ΔZeffective(combined) (HR = 0.43, 95% CI: 0.21–0.87, p = 0.019) were associated with favorable OS; the largest reduction in ΔZeffective(combined) was associated with higher response (OR = 2.79, 95% CI: 1.12–6.94, p = 0.027). The largest reduction in ΔHU(combined) was solely associated with OS in univariate analysis (HR 0.45, 95% CI: 0.23–0.91). Reduction in SOD ≥ 30% at 1 month was not associated with outcomes (p > 0.075). Conclusions: Early reductions at 1 month in ΔIC(combined) and ΔZeffective(combined) are associated with favorable outcomes in patients with mRCC. This information may reassure physicians and patients about treatment strategy. Key Points: • Early reductions following 1 month of therapy in spectral dual-layer detector CT-derived iodine concentration and the effective atomic number (Zeffective) are independent biomarkers for better overall survival in patients with metastatic renal cell carcinoma. • Early reduction after 1 month of therapy in the effective atomic number (Zeffective) is an independent imaging biomarker for better treatment response metastatic renal cell carcinoma.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | European Radiology |
| Vol/bind | 32 |
| Sider (fra-til) | 7323-7334 |
| ISSN | 0938-7994 |
| DOI | |
| Status | Udgivet - nov. 2022 |
Bibliografisk note
Funding Information:Aska Drljevic-Nielsen reports a research grant from Ipsen and teaching fees from Philips. Frede Donskov reports research grants from Ipsen, Pfizer, MSD, and The Health Research Foundation, Central Denmark Region. Michael Brun Andersen reports teaching fees from Philips and Boehringer Ingelheim. No potential conflicts of interest were disclosed by the other authors.